Home / Deep Research / Fibrocartilaginous Embolism

Fibrocartilaginous Embolism

1. Disease Information

2026-05-05
Falcon MONDO:0023152 Model: Edison Scientific Literature 49 citations

1. Disease Information

1.1 Concise overview / definition

Fibrocartilaginous embolism (FCE) is an ischemic myelopathy (spinal cord infarction) caused by embolization of fibrocartilaginous material, presumed to originate from the nucleus pulposus of the intervertebral disc, into vessels supplying the spinal cord. In clinical practice it is typically a diagnosis of exclusion because definitive confirmation is usually postmortem or via biopsy/histopathology. (cuello2014acutecervicalmyelopathy pages 1-2, taous2023spinalcordinfarction pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

1.2 Synonyms / alternative names

1.3 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

Within the retrieved full-text evidence, explicit ontology identifiers (OMIM, Orphanet, ICD-10/ICD-11, MeSH, MONDO) were not stated. Therefore, this report cannot provide validated identifier mappings from the present evidence set. (cuello2014acutecervicalmyelopathy pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

1.4 Evidence source type

Evidence is primarily: - Human clinical: case reports, systematic reviews, and SCI cohorts with FCE as a subgroup (cuello2014acutecervicalmyelopathy pages 1-2, castello2023spinalcordinfarction pages 1-2, mateen2011clinicallysuspectedfibrocartilaginous pages 6-7) - Veterinary clinical/pathology: naturally occurring FCEM in dogs/cats with histologic confirmation and MRI phenotype (risio2010fibrocartilaginousembolicmyelopathy pages 6-8, togawa2024outcomeinparaplegic pages 1-2) - Clinical registry/trial record: observational SCI cohort explicitly including FCE criteria (NCT04372758 chunk 1)

2. Etiology

2.1 Primary causal factors

Mechanistic cause (current understanding): migration/embolization of nucleus pulposus–derived fibrocartilaginous material into spinal cord vasculature causing arterial occlusion and infarction. (taous2023spinalcordinfarction pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 5-6, abdelrazek2016fibrocartilaginousembolisma pages 1-2)

2.2 Risk factors

FCE often follows minor trauma or mechanical/pressure events that plausibly increase intradiscal or intra-vertebral pressure (e.g., heavy lifting, physical exertion, bending, Valsalva-like maneuvers). (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, zalewski2019characteristicsofspontaneous pages 3-4, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

Quantitative examples: - In a Mayo clinically suspected FCE cohort, 7/9 (78%) had a precipitating event within 24 hours (motor vehicle accident, heavy lifting, exertion, bending). (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3) - In spontaneous SCI more broadly, 33/133 (25%) reported a precipitating physical maneuver (e.g., lifting/Valsalva). (zalewski2019characteristicsofspontaneous pages 3-4)

Vascular risk factors: Many patients with spontaneous SCI have vascular risk factors, but FCE is considered particularly in patients with fewer traditional vascular risk factors and supportive disc/vertebral imaging changes; some proposed criteria exclude patients with >2 vascular risk factors. (mateen2011clinicallysuspectedfibrocartilaginous pages 7-8, zalewski2019characteristicsofspontaneous pages 1-2)

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved evidence. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

2.4 Gene–environment interactions

No validated gene–environment interactions were identified for human FCE in the retrieved evidence. (abdelrazek2016fibrocartilaginousembolisma pages 5-6)

3. Phenotypes (clinical presentation)

3.1 Core phenotype spectrum

Typical presentation involves: - Acute back/neck pain followed by rapid neurological deficit (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, cuello2014acutecervicalmyelopathy pages 1-2) - Acute paresis/paralysis (paraparesis/paraplegia or quadriparesis/quadriplegia), often initially flaccid with hyporeflexia (alfarsi2023spinalcordinfarct pages 2-4, chukwudelunzu2025fibrocartilaginousembolismspinala pages 2-3) - Sensory level; commonly selective impairment of pain/temperature (spinothalamic) with relative dorsal column sparing in anterior spinal artery territory presentations (alfarsi2023spinalcordinfarct pages 2-4, zalewski2019characteristicsofspontaneous pages 3-4) - Autonomic dysfunction (neurogenic bladder/bowel) (alfarsi2023spinalcordinfarct pages 2-4)

3.2 Age of onset and temporal profile

3.3 Severity/progression

Deficits typically progress over minutes to hours to a nadir and then stabilize; severe disability is common, but recovery varies depending on lesion extent and level and access to rehabilitation. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7, shah2018fibrocartilaginousemboliin pages 4-4)

3.4 Suggested HPO terms (non-exhaustive)

Based on the above clinical features: - Acute pain: Back pain (HP:0003418); Neck pain (HP:0000467) - Motor deficits: Paraplegia (HP:0003401); Quadriplegia (HP:0003293); Muscle weakness (HP:0001324) - Sensory deficits: Loss of pain sensation (HP:0007012); Sensory level (HP:0033725) (term availability may vary across HPO releases) - Autonomic: Neurogenic bladder (HP:0000010); Urinary retention (HP:0000016)

(These HPO suggestions are ontology-mapping aids; the retrieved papers describe the phenotypes but do not provide HPO codes.) (alfarsi2023spinalcordinfarct pages 2-4, mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, zalewski2019characteristicsofspontaneous pages 3-4)

4. Genetic / Molecular Information

4.1 Causal genes / variants

No causal genes, pathogenic germline variants, or inherited pattern are supported by the retrieved evidence. Human FCE is primarily treated as a mechanical/vascular phenomenon rather than a monogenic disease. (abdelrazek2016fibrocartilaginousembolisma pages 5-6)

4.2 Molecular profiling / omics

No transcriptomic/proteomic/metabolomic signatures specific to human FCE were identified in the retrieved evidence. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7)

5. Environmental Information

5.1 Environmental/lifestyle triggers

The most consistently reported environmental/behavioral correlates are activities increasing spinal load/pressure, including heavy lifting and physical exertion, and other minor traumatic or Valsalva-like events. (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, zalewski2019characteristicsofspontaneous pages 3-4)

5.2 Infectious agents

No infectious etiology is supported; infectious/inflammatory causes are part of the differential diagnosis to be excluded. (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, abdelrazek2016fibrocartilaginousembolisma pages 5-6)

6. Mechanism / Pathophysiology

6.1 Causal chain (trigger → lesion → symptoms)

  1. Trigger (often minor exertion/trauma/pressure event) temporally associated with symptom onset (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3, abdelrazek2016fibrocartilaginousembolisma pages 5-6)
  2. Disc-derived fibrocartilage enters vasculature (nucleus pulposus material migration/embolization) (taous2023spinalcordinfarction pages 1-2, abdelrazek2016fibrocartilaginousembolisma pages 1-2)
  3. Vascular occlusion (often radicular/anterior spinal artery territory) → spinal cord ischemia and infarction (manara2010spinalcordinfarction pages 3-4, cuello2014acutecervicalmyelopathy pages 1-2)
  4. Clinical syndrome of acute myelopathy: pain, rapid paralysis/weakness, sensory level, autonomic dysfunction (alfarsi2023spinalcordinfarct pages 2-4, mateen2011clinicallysuspectedfibrocartilaginous pages 2-3)

6.2 Upstream vs downstream processes

6.3 Suggested GO biological process terms (conceptual mapping)

  • Ischemic process / response to hypoxia (e.g., “response to hypoxia”, “cell death”) consistent with infarction biology (supported indirectly via DWI evidence of cytotoxic edema rather than specific molecular assays). (manara2010spinalcordinfarction pages 3-4)

6.4 Suggested Cell Ontology (CL) cell types

Primary tissue affected is spinal cord gray/white matter; cell types implicated in ischemic injury include: - Spinal cord neuron populations (especially anterior horn motor neurons in ASA territory) (manara2010spinalcordinfarction pages 3-4) - Glial cells involved in infarct evolution (inferred from ischemic myelopathy context; not directly profiled here). (manara2010spinalcordinfarction pages 3-4)

7. Anatomical Structures Affected

7.1 Organ/system level

7.2 Localization patterns

7.3 Suggested UBERON terms (conceptual mapping)

  • Spinal cord (UBERON:0002240)
  • Segmental localization (cervical/thoracic/lumbar spinal cord)

8. Temporal Development

8.1 Onset

Hyperacute/acute onset is characteristic. - Mayo suspected-FCE cohort: maximal deficits within <12 h in all cases (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3) - Spontaneous SCI cohort: nadir within 12 h in 77% (zalewski2019characteristicsofspontaneous pages 1-2)

8.2 Course

Often stabilizes after reaching nadir; longer-term course depends on infarct size/level and rehabilitation. (shah2018fibrocartilaginousemboliin pages 4-4)

9. Inheritance and Population

9.1 Epidemiology

Population incidence/prevalence for human FCE remains poorly defined; however, proportions within SCI cohorts are reported: - Mayo SCI cohort: 9/164 (5.5%; 95% CI 2.5–10.2%) clinically suspected FCE among acute spinal cord infarctions. (mateen2011clinicallysuspectedfibrocartilaginous pages 1-2) - 2023 single-center 41-patient SCI series: fibrocartilaginous embolism 14.6% (6 cases); etiology undetermined 29.3%. (castello2023spinalcordinfarction pages 1-2, castello2023spinalcordinfarction pages 5-7)

9.2 Sex and age distribution

10. Diagnostics

10.1 Key clinical/imaging tests

MRI spine (core test): - T2 patterns typical for SCI include “owl eyes” and “pencil-like” hyperintensity (SCI data; also leveraged in FCE suspicion). (zalewski2019characteristicsofspontaneous pages 3-4, zalewski2019characteristicsofspontaneous pages 1-2) - FCE case reports emphasize cord swelling and T2 hyperintensity, often without early enhancement; adjacent disc pathology or Schmorl nodes can support FCE mechanism. (yamaguchi2019fibrocartilaginousembolismof pages 5-8, alfarsi2023spinalcordinfarct pages 2-4)

Diffusion-weighted imaging (DWI/ADC): - Helps distinguish cytotoxic (ischemic) from vasogenic (inflammatory) edema; recommended for acute myelopathy workups. (manara2010spinalcordinfarction pages 3-4, manara2010spinalcordinfarction pages 4-5) - In spontaneous SCI cohort: DWI/ADC restriction in 19/29 (67%). (zalewski2019characteristicsofspontaneous pages 3-4)

CSF: usually normal or mild nonspecific abnormalities; used to exclude inflammation. - In spontaneous SCI: mild inflammation in 7/89 (8%) (elevated nucleated cells). (zalewski2019characteristicsofspontaneous pages 1-2)

10.2 Proposed diagnostic criteria / algorithms (expert consensus-level)

10.3 Differential diagnosis

Frequently confounded with inflammatory myelopathies (e.g., transverse myelitis) and other acute myelopathies; multiple reports note misdiagnosis risk and delay. (alfarsi2023spinalcordinfarct pages 2-4, zalewski2019characteristicsofspontaneous pages 1-2)

10.4 Pathology

Definitive diagnosis is histopathologic identification of fibrocartilaginous material within spinal cord vessels (often autopsy). (risio2010fibrocartilaginousembolicmyelopathy pages 6-8, abdelrazek2016fibrocartilaginousembolisma pages 1-2)

11. Outcome / Prognosis

11.1 Human prognosis

11.2 Prognostic factors (general SCI / FCE-inferred)

Severity at onset and lesion extent influence recovery; SCI literature identifies older age, vascular risk factors, and anterior spinal artery watershed involvement as worse prognostic indicators. (mcbride2024nonsurgicalspinalcord pages 3-4)

12. Treatment

12.1 Pharmacotherapy and acute interventions

Evidence does not support a specific proven acute therapy for FCE. - In Mayo suspected-FCE series, IV steroids, plasma exchange, IV heparin, IVIG, and decompressive surgery did not yield meaningful acute improvement. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7) - Some cases are treated with antiplatelet therapy (e.g., aspirin) after excluding inflammatory etiologies; this is largely extrapolated rather than evidence-based for FCE specifically. (alfarsi2023spinalcordinfarct pages 2-4, castello2023spinalcordinfarction pages 5-7)

12.2 Neurocritical care / neuroprotection (case-based)

A pediatric illustrative case applied continuous CSF drainage plus mean arterial pressure augmentation (permissive hypertension) and steroids with substantial neurological improvement; this is hypothesis-generating and extrapolated from aortic surgery spinal cord protection principles. (fedaravicius2021successfulmanagementof pages 1-2)

12.3 Rehabilitation (real-world implementation)

Rehabilitation is consistently emphasized. - Pediatric rehabilitation case literature reports substantial functional gains after intensive inpatient rehabilitation and advocates early initiation of comprehensive rehab. (shah2018fibrocartilaginousemboliin pages 4-4) - In an inpatient rehab cohort of probable FCEM (31 patients), functional scores improved (motor FIM increased from 36 to 69 during rehab), though many still used wheelchairs as primary mobility at discharge. (moore2018fibrocartilaginousembolicmyelopathy pages 1-2)

12.4 MAXO term suggestions (conceptual mapping)

13. Prevention

No validated primary prevention strategy exists because FCE is rare, unpredictable, and typically associated with nonspecific mechanical triggers. Practical prevention is therefore limited to general spine safety and vascular-risk management when appropriate, but this is not evidence-based for FCE prevention specifically in the retrieved literature. (abdelrazek2016fibrocartilaginousembolisma pages 5-6)

14. Other Species / Natural Disease

14.1 Naturally occurring veterinary analogs

In veterinary neurology, fibrocartilaginous embolic myelopathy (FCEM) is a well-recognized cause of peracute noncompressive myelopathy in dogs/cats, with diagnosis definitively confirmed by histology showing fibrocartilaginous material in spinal vessels. (risio2010fibrocartilaginousembolicmyelopathy pages 6-8)

14.2 Veterinary outcome statistics (useful for comparative prognosis biology)

In a 2024 cohort of paraplegic dogs with thoracolumbar FCEM/ANNPE: - Deep pain positive: 9/14 (64.3%) regained independent ambulation - Deep pain negative: 1/12 (8.3%) regained independent ambulation - Deep pain negative status strongly predicted poor recovery (OR 47.40). (togawa2024outcomeinparaplegic pages 1-2)

These naturally occurring datasets support the central prognostic role of initial neurologic severity and can inform translational hypotheses, but they are not direct human clinical evidence. (togawa2024outcomeinparaplegic pages 1-2, risio2010fibrocartilaginousembolicmyelopathy pages 6-8)

15. Model Organisms

No engineered genetic model organism systems were identified in the retrieved evidence. The most relevant “models” are naturally occurring veterinary FCEM cases and imaging/clinical cohorts, which provide translationally relevant ischemic myelopathy phenotypes and opportunities for biomarker and neuroprotection research. (risio2010fibrocartilaginousembolicmyelopathy pages 6-8, togawa2024outcomeinparaplegic pages 1-2)

Recent developments and latest research emphasis (2023–2024)

  • Human cohort-level update (2023): a 41-patient spinal cord infarction series reported fibrocartilaginous embolism as 14.6% of etiologies and documented major long-term disability (only 29.2% walking unaided at median 24 months) and substantial mortality, underscoring persistent unmet needs in diagnosis and post-acute care. (castello2023spinalcordinfarction pages 1-2, castello2023spinalcordinfarction pages 5-7)
  • Prognosis synthesis (2024): a long-term follow-up case series/review context emphasizes that a large fraction of SCI remains of unclear etiology in published studies (24–74%) and that long-term disability is common, with prognosis linked to initial severity and risk factors. (mcbride2024nonsurgicalspinalcord pages 3-4)
  • Veterinary prognosis (2024): robust prognostic discrimination using deep pain sensation in severe FCEM/ANNPE provides an example of clinically actionable predictors in a natural disease analog. (togawa2024outcomeinparaplegic pages 1-2)

Clinical trials / registries

  • ClinicalTrials.gov NCT04372758 (EDMIAS): completed retrospective observational cohort (n=60) aimed at characterizing acute spontaneous SCI (2010–2020) and explicitly includes evaluation/application of fibrocartilaginous embolism criteria (2015) as a secondary outcome, reflecting ongoing efforts to operationalize FCE diagnosis within SCI research frameworks. URL: https://clinicaltrials.gov/study/NCT04372758 (NCT04372758 chunk 1)

Key limitations / data gaps

References

  1. (cuello2014acutecervicalmyelopathy pages 1-2): Juan P. Cuello, Santiago Ortega-Gutierrez, Guillermo Linares, Sachin Agarwal, Alyson Cunningham, Jay P. Mohr, Stephan A. Mayer, Randolph S. Marshall, Jan Claassen, Neeraj Badjatia, Mitchel S.V. Elkind, and Kiwon Lee. Acute cervical myelopathy due to presumed fibrocartilaginous embolism: a case report and systematic review of the literature. Journal of Spinal Disorders and Techniques, 27:E276–E281, Dec 2014. URL: https://doi.org/10.1097/bsd.0000000000000115, doi:10.1097/bsd.0000000000000115. This article has 18 citations.

  2. (mateen2011clinicallysuspectedfibrocartilaginous pages 6-7): F. Mateen, F. Mateen, Priya Monrad, A. L. Hunderfund, Carrie E. Robertson, and E. J. Sorenson. Clinically suspected fibrocartilaginous embolism: clinical characteristics, treatments, and outcomes. European Journal of Neurology, 18:218-225, Feb 2011. URL: https://doi.org/10.1111/j.1468-1331.2010.03200.x, doi:10.1111/j.1468-1331.2010.03200.x. This article has 93 citations and is from a domain leading peer-reviewed journal.

  3. (abdelrazek2016fibrocartilaginousembolisma pages 5-6): Mahmoud A. AbdelRazek, Ashkan Mowla, Salman Farooq, Nicholas Silvestri, Robert Sawyer, and Gil Wolfe. Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria. The Journal of Spinal Cord Medicine, 39:146-154, Feb 2016. URL: https://doi.org/10.1080/10790268.2015.1116726, doi:10.1080/10790268.2015.1116726. This article has 116 citations.

  4. (taous2023spinalcordinfarction pages 1-2): Abdellah Taous, Taoufik Boubga, Tarik Boulahri, Soufiane Belabbes, Taoufik Africha, Omar Boulahroud, and Maha Ait Berri. Spinal cord infarction owing to likely fibrocartilaginous embolism. SAS Journal of Medicine, 9:1207-1209, Nov 2023. URL: https://doi.org/10.36347/sasjm.2023.v09i11.015, doi:10.36347/sasjm.2023.v09i11.015. This article has 0 citations.

  5. (alfarsi2023spinalcordinfarct pages 2-4): Said A Al-Farsi, Haifa Al-Abri, Eiman Al-Ajmi, and Abdullah Al-Asmi. Spinal cord infarct due to fibrocartilaginous embolism in an adolescent boy: a case report and literature review. Cureus, Apr 2023. URL: https://doi.org/10.7759/cureus.37319, doi:10.7759/cureus.37319. This article has 7 citations.

  6. (mateen2011clinicallysuspectedfibrocartilaginous pages 1-2): F. Mateen, F. Mateen, Priya Monrad, A. L. Hunderfund, Carrie E. Robertson, and E. J. Sorenson. Clinically suspected fibrocartilaginous embolism: clinical characteristics, treatments, and outcomes. European Journal of Neurology, 18:218-225, Feb 2011. URL: https://doi.org/10.1111/j.1468-1331.2010.03200.x, doi:10.1111/j.1468-1331.2010.03200.x. This article has 93 citations and is from a domain leading peer-reviewed journal.

  7. (mateen2011clinicallysuspectedfibrocartilaginous pages 2-3): F. Mateen, F. Mateen, Priya Monrad, A. L. Hunderfund, Carrie E. Robertson, and E. J. Sorenson. Clinically suspected fibrocartilaginous embolism: clinical characteristics, treatments, and outcomes. European Journal of Neurology, 18:218-225, Feb 2011. URL: https://doi.org/10.1111/j.1468-1331.2010.03200.x, doi:10.1111/j.1468-1331.2010.03200.x. This article has 93 citations and is from a domain leading peer-reviewed journal.

  8. (mateen2011clinicallysuspectedfibrocartilaginous pages 7-8): F. Mateen, F. Mateen, Priya Monrad, A. L. Hunderfund, Carrie E. Robertson, and E. J. Sorenson. Clinically suspected fibrocartilaginous embolism: clinical characteristics, treatments, and outcomes. European Journal of Neurology, 18:218-225, Feb 2011. URL: https://doi.org/10.1111/j.1468-1331.2010.03200.x, doi:10.1111/j.1468-1331.2010.03200.x. This article has 93 citations and is from a domain leading peer-reviewed journal.

  9. (risio2010fibrocartilaginousembolicmyelopathy pages 6-8): Luisa De Risio and Simon R. Platt. Fibrocartilaginous embolic myelopathy in small animals. The Veterinary clinics of North America. Small animal practice, 40 5:859-69, Sep 2010. URL: https://doi.org/10.1016/j.cvsm.2010.05.003, doi:10.1016/j.cvsm.2010.05.003. This article has 121 citations.

  10. (manara2010spinalcordinfarction pages 1-3): Renzo Manara, Milena Calderone, Maria Savina Severino, Valentina Citton, Irene Toldo, Anna Maria Laverda, and Stefano Sartori. Spinal cord infarction due to fibrocartilaginous embolization: the role of diffusion weighted imaging and short-tau inversion recovery sequences. Journal of Child Neurology, 25:1024-1028, Mar 2010. URL: https://doi.org/10.1177/0883073809355822, doi:10.1177/0883073809355822. This article has 34 citations and is from a peer-reviewed journal.

  11. (manara2010spinalcordinfarction pages 3-4): Renzo Manara, Milena Calderone, Maria Savina Severino, Valentina Citton, Irene Toldo, Anna Maria Laverda, and Stefano Sartori. Spinal cord infarction due to fibrocartilaginous embolization: the role of diffusion weighted imaging and short-tau inversion recovery sequences. Journal of Child Neurology, 25:1024-1028, Mar 2010. URL: https://doi.org/10.1177/0883073809355822, doi:10.1177/0883073809355822. This article has 34 citations and is from a peer-reviewed journal.

  12. (yamaguchi2019fibrocartilaginousembolismof pages 5-8): Hiroshi Yamaguchi, Hiroaki Nagase, Masahiro Nishiyama, Shoichi Tokumoto, Daisaku Toyoshima, Yoshinobu Akasaka, Azusa Maruyama, and Kazumoto Iijima. Fibrocartilaginous embolism of the spinal cord in children: a case report and review of literature. Pediatric neurology, 99:3-6, Oct 2019. URL: https://doi.org/10.1016/j.pediatrneurol.2019.04.013, doi:10.1016/j.pediatrneurol.2019.04.013. This article has 29 citations and is from a peer-reviewed journal.

  13. (castello2023spinalcordinfarction pages 1-2): V. Ros Castelló, A. Sánchez Sánchez, E. Natera Villalba, A. Gómez López, P. Parra, F. Rodríguez Jorge, J. Buisán Catevilla, N. García Barragán, J. Masjuán, and Í. Corral. Spinal cord infarction: aetiology, imaging findings, and prognostic factors in a series of 41 patients. Neurología (English Edition), 38:391-398, Jul 2023. URL: https://doi.org/10.1016/j.nrleng.2020.11.004, doi:10.1016/j.nrleng.2020.11.004. This article has 20 citations.

  14. (manara2010spinalcordinfarction pages 4-5): Renzo Manara, Milena Calderone, Maria Savina Severino, Valentina Citton, Irene Toldo, Anna Maria Laverda, and Stefano Sartori. Spinal cord infarction due to fibrocartilaginous embolization: the role of diffusion weighted imaging and short-tau inversion recovery sequences. Journal of Child Neurology, 25:1024-1028, Mar 2010. URL: https://doi.org/10.1177/0883073809355822, doi:10.1177/0883073809355822. This article has 34 citations and is from a peer-reviewed journal.

  15. (castello2023spinalcordinfarction pages 5-7): V. Ros Castelló, A. Sánchez Sánchez, E. Natera Villalba, A. Gómez López, P. Parra, F. Rodríguez Jorge, J. Buisán Catevilla, N. García Barragán, J. Masjuán, and Í. Corral. Spinal cord infarction: aetiology, imaging findings, and prognostic factors in a series of 41 patients. Neurología (English Edition), 38:391-398, Jul 2023. URL: https://doi.org/10.1016/j.nrleng.2020.11.004, doi:10.1016/j.nrleng.2020.11.004. This article has 20 citations.

  16. (mcbride2024nonsurgicalspinalcord pages 3-4): Fionán McBride, Jane Anketell, Gavin V. McDonnell, Suzanne Maguire, and Karen M. Doherty. Non-surgical spinal cord infarction: case series & long-term follow-up of functional outcome. Spinal Cord Series and Cases, Oct 2024. URL: https://doi.org/10.1038/s41394-024-00665-y, doi:10.1038/s41394-024-00665-y. This article has 1 citations and is from a peer-reviewed journal.

  17. (NCT04372758 chunk 1): Descriptive Study of Acute Spontaneous Spinal Cord Infarction. University Hospital, Montpellier. 2020. ClinicalTrials.gov Identifier: NCT04372758

  18. (abdelrazek2016fibrocartilaginousembolisma pages 1-2): Mahmoud A. AbdelRazek, Ashkan Mowla, Salman Farooq, Nicholas Silvestri, Robert Sawyer, and Gil Wolfe. Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria. The Journal of Spinal Cord Medicine, 39:146-154, Feb 2016. URL: https://doi.org/10.1080/10790268.2015.1116726, doi:10.1080/10790268.2015.1116726. This article has 116 citations.

  19. (togawa2024outcomeinparaplegic pages 1-2): Go Togawa, Melissa J. Lewis, and Dillon Devathasan. Outcome in paraplegic dogs with or without pain perception due to thoracolumbar fibrocartilaginous embolic myelopathy or acute non-compressive nucleus pulposus extrusion. Frontiers in Veterinary Science, May 2024. URL: https://doi.org/10.3389/fvets.2024.1406843, doi:10.3389/fvets.2024.1406843. This article has 7 citations and is from a peer-reviewed journal.

  20. (zalewski2019characteristicsofspontaneous pages 3-4): Nicholas L. Zalewski, Alejandro A. Rabinstein, Karl N. Krecke, Robert D. Brown, Eelco F. M. Wijdicks, Brian G. Weinshenker, Timothy J. Kaufmann, Jonathan M. Morris, Allen J. Aksamit, J. D. Bartleson, Giuseppe Lanzino, Melissa M. Blessing, and Eoin P. Flanagan. Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria. JAMA Neurology, 76:56–63, Jan 2019. URL: https://doi.org/10.1001/jamaneurol.2018.2734, doi:10.1001/jamaneurol.2018.2734. This article has 249 citations and is from a highest quality peer-reviewed journal.

  21. (zalewski2019characteristicsofspontaneous pages 1-2): Nicholas L. Zalewski, Alejandro A. Rabinstein, Karl N. Krecke, Robert D. Brown, Eelco F. M. Wijdicks, Brian G. Weinshenker, Timothy J. Kaufmann, Jonathan M. Morris, Allen J. Aksamit, J. D. Bartleson, Giuseppe Lanzino, Melissa M. Blessing, and Eoin P. Flanagan. Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria. JAMA Neurology, 76:56–63, Jan 2019. URL: https://doi.org/10.1001/jamaneurol.2018.2734, doi:10.1001/jamaneurol.2018.2734. This article has 249 citations and is from a highest quality peer-reviewed journal.

  22. (chukwudelunzu2025fibrocartilaginousembolismspinala pages 2-3): FE Chukwudelunzu and T Young. Fibrocartilaginous embolism spinal cord infarction, mistaken for glial fibrillary acidic protein autoimmune transverse myelitis: a case report. Unknown journal, 2025.

  23. (shah2018fibrocartilaginousemboliin pages 4-4): Supriya Shah and Phillip Bryant. Fibrocartilaginous emboli in the pediatric population: the role of rehabilitation in facilitating functional recovery. Journal of Pediatric Rehabilitation Medicine, 11:53-56, Mar 2018. URL: https://doi.org/10.3233/prm-170502, doi:10.3233/prm-170502. This article has 11 citations.

  24. (fedaravicius2021successfulmanagementof pages 1-2): Augustinas Fedaravičius, Yael Feinstein, Isaac Lazar, Micky Gidon, Ilan Shelef, Elad Avraham, Arimantas Tamašauskas, and Israel Melamed. Successful management of spinal cord ischemia in a pediatric patient with fibrocartilaginous embolism: illustrative case. Journal of Neurosurgery: Case Lessons, Sep 2021. URL: https://doi.org/10.3171/case21380, doi:10.3171/case21380. This article has 5 citations.

  25. (moore2018fibrocartilaginousembolicmyelopathy pages 1-2): Brittany J. Moore, Anna M. Batterson, Marianne T. Luetmer, and Ronald K. Reeves. Fibrocartilaginous embolic myelopathy: demographics, clinical presentation, and functional outcomes. Spinal Cord, 56:1144-1150, May 2018. URL: https://doi.org/10.1038/s41393-018-0159-y, doi:10.1038/s41393-018-0159-y. This article has 12 citations and is from a peer-reviewed journal.